Mirum Pharmaceuticals price target lowered to $132 from $140 at Citizens

Citizens analyst Jonathan Wolleben lowered the firm’s price target on Mirum Pharmaceuticals (MIRM) to $132 from $140 and keeps an Outperform rating on the shares. Mirum is approaching key pivotal readouts in Primary Sclerosing Cholangitis and hepatitis delta virus that could substantially expand its hepatology franchise, the analyst tells investors in a research note. Mirum enters 2026 with strong commercial momentum and a slate of near-term catalysts poised to unlock meaningful long-term value with four pivotal readouts over the next 18 months, the firm says.